RxDoctor Payments Data

Brent Campbell, MD

Urology · Lufkin, TXNPI 1326058363

Payments from drug & device makers

$8,203in general payments, 2019–2025

Across 359 payments — averaging $22.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Johnson & Johnson$1K
  • Pfizer$879
  • Astellas Pharma US Inc$819
  • Sumitomo Pharma America, Inc.$641
  • Boston Scientific$514
  • plus $2K from 14 others

What the payments were for

  • Speaking & faculty fees$4736%
  • Food & beverage$7,37890%
  • Education$3534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,203 in reported general payments places this provider in the 65th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$718,938
Medicare patients
840
Services billed
13,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide75$1,133,930
ErleadaApalutamide66$985,061
FirmagonDegarelix Acetate356$193,426
XgevaDenosumab33$103,105
MyrbetriqMirabegron193$99,224
GemtesaVibegron159$87,793
EligardLeuprolide Acetate19$50,125
ElmironPentosan Polysulfate Sodium20$24,572
Mirabegron ErMirabegron17$9,031
Estradiol121$8,337
Tamsulosin Hcl495$4,646
Ciprofloxacin Hcl593$4,191
Letrozole190$3,582
Oxybutynin Chloride66$1,763
Imipramine Hcl80$1,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$819$1,233,154268 claims
Johnson & JohnsonErleada$1,243$985,06166 claims
AmgenXgeva$20$103,10533 claims
Sumitomo Pharma America, Inc.Gemtesa$641$87,793159 claims
Tolmar Pharmaceuticals, Inc.Eligard$63$50,12519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 878 urology providers in Texas.

Other urology in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →